Force pharma companies to provide drugs for rare cancer trials, UK govt told

MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Insilico lands potential $2.5bn AI biotech partnership

22 June 2026 The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.

Biotechnology

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

4 June 2026 The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.

Biotechnology

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

More features

GLP-1 patents and Africa: The COVID-19 lessons we still have not learned

Cooley Asia transactions duo make rival firm move

Insilico lands potential $2.5bn AI biotech partnership

‘Blatant imitation’: Indian court blocks copycat pharma branding

UPC hands Occlutech second win against Chinese medtech company in a month

US life sciences damages averaged $33.5m between 2019-2025

Quantum and photonics tech licensing expert joins EIP

Court upholds $83m sequencing verdict and sets royalty rate

Force pharma companies to provide drugs for rare cancer trials, UK govt told

More on this story

Editor's picks

Editor's picks

More features